Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Fusco

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
BMC Primary Care|November 24, 2022
HIV retention in care: results and lessons learned from the Positive Pathways Implementation TrialMichael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
HIV Medicine|August 26, 2024
Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort studyRicky K Hsu, Laurence Brunet, Philip C Lackey, et al.
AIDS Patient Care and Stds|March 28, 2026
Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment OutcomesKaram Mounzer, Laurence Brunet, Ricky K Hsu, et al.
AIDS Research and Therapy|October 27, 2024
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United StatesGerald Pierone, Jennifer S Fusco, Laurence Brunet, et al.
Toxicon : Official Journal of the International Society on Toxinology|June 10, 2022
CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in miceLuciano S Fusco, María M Pascual, David Hernandez, et al.
Toxicon : Official Journal of the International Society on Toxinology|July 16, 2022
Corrigendum to "CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice" [Toxicon 215 (2022) 28-36]Luciano S Fusco, María M Pascual, David Hernandez, et al.
Toxicology Letters|July 2, 2015
P9a(Cdt-PLA2) from Crotalus durissus terrificus as good immunogen to be employed in the production of crotalic anti-PLA2 IgGLuciano S Fusco, Juan Pablo Rodríguez, Frank Torres-Huaco, et al.
La Clinica Terapeutica|November 24, 2004
[The Moschkowitz syndrome in emergency department. Case report]M Suppa, N Di Lallo, V Scarponi, et al.
Journal of the International AIDS Society|April 10, 2021
Weight gain before and after switch from TDF to TAF in a U.S. cohort studyPatrick Wg Mallon, Laurence Brunet, Ricky K Hsu, et al.
AIDS Research and Therapy|January 18, 2019
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA<sup>®</sup> observational database: a cohort studyKaram Mounzer, Ricky Hsu, Jennifer S Fusco, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
BMC Primary Care|November 24, 2022
HIV retention in care: results and lessons learned from the Positive Pathways Implementation TrialMichael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
HIV Medicine|August 26, 2024
Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort studyRicky K Hsu, Laurence Brunet, Philip C Lackey, et al.
AIDS Patient Care and Stds|March 28, 2026
Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment OutcomesKaram Mounzer, Laurence Brunet, Ricky K Hsu, et al.
AIDS Research and Therapy|October 27, 2024
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United StatesGerald Pierone, Jennifer S Fusco, Laurence Brunet, et al.
Toxicon : Official Journal of the International Society on Toxinology|June 10, 2022
CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in miceLuciano S Fusco, María M Pascual, David Hernandez, et al.
Toxicon : Official Journal of the International Society on Toxinology|July 16, 2022
Corrigendum to "CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice" [Toxicon 215 (2022) 28-36]Luciano S Fusco, María M Pascual, David Hernandez, et al.
Toxicology Letters|July 2, 2015
P9a(Cdt-PLA2) from Crotalus durissus terrificus as good immunogen to be employed in the production of crotalic anti-PLA2 IgGLuciano S Fusco, Juan Pablo Rodríguez, Frank Torres-Huaco, et al.
La Clinica Terapeutica|November 24, 2004
[The Moschkowitz syndrome in emergency department. Case report]M Suppa, N Di Lallo, V Scarponi, et al.
Journal of the International AIDS Society|April 10, 2021
Weight gain before and after switch from TDF to TAF in a U.S. cohort studyPatrick Wg Mallon, Laurence Brunet, Ricky K Hsu, et al.
AIDS Research and Therapy|January 18, 2019
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA<sup>®</sup> observational database: a cohort studyKaram Mounzer, Ricky Hsu, Jennifer S Fusco, et al.
Pageof 8